Recently, a higher immunohistochemical expression of PD-L1 known to be associated with immune evasion in a variety of malignancies, including TNBC, was identified in breast carcinomas with medullary features, in which might represent a marker of susceptibility to PD-1/PD-L1 inhibitor therapies [46]. The gene discussed is CD274; the disease is breast carcinoma.